{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-109256","form_type":"8-K","ticker":"SLS","cik":"0001390478","company_name":"SELLAS Life Sciences Group, Inc.","filed_at":"2023-10-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.834385+00:00","generated_at":"2026-06-09T23:09:04.986231+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"SELLAS reports positive Phase 2a topline data for SLS009 in AML; first patient achieved complete response","bullets":["First of 5 enrolled r/r AML patients achieved complete response, remains alive in 5th month of treatment.","All 5 patients alive at last follow-up; 4 continue treatment; anti-leukemic effects seen in all.","No significant safety issues observed at 45 mg dose level; median OS for venetoclax-failure AML is ~2.5 months.","SLS009 is first CDK9 inhibitor to achieve CR in combination with AZA/VEN in venetoclax-resistant AML.","Topline data for 60 mg dose expected later this quarter; multiple registrational opportunities cited."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-109256","json":"https://secwatch.observer/filing/0001104659-23-109256.json","markdown":"https://secwatch.observer/filing/0001104659-23-109256.md","text":"https://secwatch.observer/filing/0001104659-23-109256.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1390478/000110465923109256/0001104659-23-109256-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1390478/000110465923109256/tm2328502d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T23:09:04.986231+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}